このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ADC Therapeutics 将来の成長

Future 基準チェック /26

ADC Therapeuticsは、25.5%と31.4%でそれぞれ年率25.5%で利益と収益が成長すると予測される一方、EPSはgrowで35.2%年率。

主要情報

25.5%

収益成長率

35.2%

EPS成長率

Biotechs 収益成長	24.7%
収益成長率	31.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	30 May 2024

今後の成長に関する最新情報

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10

Recent updates

Limiting Concerns On ADC Therapeutics' Prospects

Jun 06

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

May 30

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Dec 29

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

Dec 14

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

May 11

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Apr 18

ADC Therapeutics stock slips after pricing stock offering by seller

Feb 02

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jan 16

Jose Carmona joins ADC Therapeutics as CFO

Dec 19

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

Nov 08

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

Sep 16

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Sep 09

ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M

Aug 09

Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts

Jul 21

業績と収益の成長予測

NYSE:ADCT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	119	-162	-100	N/A	5
12/31/2025	91	-172	-113	-145	7
12/31/2024	78	-179	-112	-145	7
3/31/2024	69	-227	-150	-147	N/A
12/31/2023	70	-240	-122	-119	N/A
9/30/2023	123	-180	-141	-140	N/A
6/30/2023	184	-183	-105	-104	N/A
3/31/2023	182	-200	-120	-120	N/A
12/31/2022	210	-157	-139	-138	N/A
9/30/2022	157	-166	-149	-146	N/A
6/30/2022	94	-187	-212	-207	N/A
3/31/2022	80	-195	-219	-212	N/A
12/31/2021	34	-230	-240	-233	N/A
9/30/2021	17	-252	-230	-223	N/A
6/30/2021	4	-200	-215	-209	N/A
3/31/2021	N/A	-254	-195	-192	N/A
12/31/2020	N/A	-246	-172	-169	N/A
9/30/2020	N/A	-226	-153	-151	N/A
6/30/2020	N/A	-237	-140	-139	N/A
3/31/2020	1	-135	-128	-126	N/A
12/31/2019	2	-116	-124	-122	N/A
9/30/2019	3	-112	-121	-118	N/A
6/30/2019	3	-111	-119	-116	N/A
3/31/2019	2	-117	-122	-118	N/A
12/31/2018	1	-123	-124	-121	N/A
12/31/2017	2	-90	N/A	-75	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ADCT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ADCT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ADCT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ADCTの収益 ( 31.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ADCTの収益 ( 31.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ADCTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

ADC Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$1.84 loss, revenue downgraded

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

Consensus EPS estimates fall by 13%, revenue upgraded

Price target increased by 19% to US$10.50

Price target increased by 12% to US$8.80

Consensus revenue estimates fall by 11%

Recent updates

Limiting Concerns On ADC Therapeutics' Prospects

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

Consensus EPS estimates upgraded to US$1.84 loss, revenue downgraded

CEO & Director recently sold US$133k worth of stock

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $105 million.

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

ADC Therapeutics SA has filed a Follow-on Equity Offering.

ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

ADC Therapeutics: Navigating A Swirling Drain

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Price target increased by 19% to US$10.50

Price target increased by 12% to US$8.80

New major risk - Share price stability

Consensus revenue estimates fall by 11%

ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

ADC Therapeutics: Slowly Moving Toward Solvency

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 20%, EPS upgraded

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ADC Therapeutics SA to Report Q2, 2023 Results on Aug 08, 2023

China National Medical Products Administration Accepts Biologics License Application and Grants Priority Review for ZYNLONTA for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA Announces Voluntary Pause in the Enrollment of New Patients in the Phase 2 LOTIS-9 Clinical Trial Evaluating ZYNLONTA

Now 31% undervalued after recent price drop

Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

High number of new directors

Price target decreased by 18% to US$9.33

ADC Therapeutics SA Announces Evolution of Board of Directors

ADC Therapeutics SA Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA(R) in Relapsed/Refractory DLBCL

ADC Therapeutics: Maybe A 2024 Story

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target increased by 9.4% to US$12.40

Consensus revenue estimates decrease by 29%, EPS upgraded

ADC Therapeutics SA Announces Updated Results from LOTIS-2 Trial to Be Presented at the European Hematology Association 2023 Hybrid Congress

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

ADC Therapeutics SA, Annual General Meeting, Jun 14, 2023

Price target increased by 8.5% to US$13.20

Price target increased by 7.4% to US$13.20

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Consensus revenue estimates fall by 16%

Price target decreased by 15% to US$11.14

Price target decreased by 8.5% to US$12.29

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $60 million.

ADC Therapeutics stock slips after pricing stock offering by seller

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

ADC Therapeutics SA Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

ADC Therapeutics Sa Appoints Jose Carmona as Chief Financial Officer

Jose Carmona joins ADC Therapeutics as CFO

Price target decreased to US$14.17

High number of new directors

Price target decreased to US$14.83

Price target increased to US$19.20

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

ADC Therapeutics SA Announces Executive Changes

ADC Therapeutics SA Announces Abstracts to Be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology